MAD2L2 and ovarian cancer: In addition, tumor-bearing mouse experiments with REV7-depleted cancer cells also demonstrated suppressed cell proliferation, increased apoptotic cells, and enhanced sensitivity to cisplatin in vivo in ovarian cancer and TGCT cells [87,91].